Skip to main content

Table 1 Baseline characteristics of study patients

From: DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes

Variable All patients
 Number 46
 Age, years 63.7 ± 1.3
 Sex male,  % 71.7
 Body mass index, kg/m2 31.1 ± 0.7
 Waist, cm 105.4 ± 2.2
 HbA1c,  %
(mmol/mol)
7.6 ± 0.2
(60 ± 2)
Risk factors
 Smoking habit,  % 13.0
 Hypertension,  % 89.1
 Total cholesterol, mg/dl 165.3 ± 5.5
 HDL cholesterol, mg/dl 49.9 ± 2.2
 LDL cholesterol, mg/dl 91.6 ± 5.1
 Triglycerides, mg/dl 119.2 ± 8.5
 Albumin/creatinine ratio (mg/g) 129.5 ± 44.1
 Creatinine, mg/dl 1.11 ± 0.06
 eGFR, ml/min/1.73 mq 75.5 ± 3.9
Complications
 Retinopathy,  % 28.2
 Neuropathy,  % 17.9
 Coronary artery disease,  % 30.4
 Peripheral arterial disease,  % 21.7
 Cerebrovascular disease,  % 47.8
Medications
 Metformin,  % 65.2
 Sulphonylurea,  % 6.5
 Repaglinide,  % 4.3
 Pioglitazone,  % 6.5
 Insulin,  % 43.4
 ACE inhibitors/ARBs,  % 76.1
 Other anti-hypertensives,  % 78.2
 Statin,  % 80.4
 Anti-platelet agents,  % 56.5
  1. Data are presented as mean ± standard error, or as percentage, where appropriate. More details can be found in [21]